Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib plus cobimetinib after radiosurgery in BRAF V600-mutant melanoma brain metastases
2017-000768-13Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in melanoma and melanoma brain metastases (MBM), sponsored by Technische Universität Dresden. Primary endpoint: Best overall response rate in the brain within two years. Started Aug 2017; status: recruiting.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanomamelanoma brain metastases (MBM)
Beyond the preview
Go deeper on 2017-000768-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000768-13.